Comparison of complications and outcomes to one year of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis
Autor: | Davide Capodanno, Sebastiano Immè, Marilena Scarabelli, Gian Paolo Ussia, Maurizio Gentile, Patrizia Aruta, Giuliana Del Campo, Corrado Tamburino, Maria Concetta Di Pasqua, Massimiliano Mulè, Marco Barbanti, Salvatore Bonura, Claudio Bonanno, Alessandra Cadoni, Carmelo Mignosa, Simona Gulino, Valeria Cammalleri, Anna Maria Pistritto |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
medicine.medical_specialty Cardiac Catheterization Time Factors Settore MED/11 - Malattie dell'Apparato Cardiovascolare Severity of Illness Index Postoperative Complications Aortic valve replacement Risk Factors Internal medicine Clinical endpoint Medicine Humans Myocardial infarction Stroke Aged Heart Valve Prosthesis Implantation business.industry Incidence Confounding Aortic Valve Stenosis medicine.disease Surgery Survival Rate Stenosis Treatment Outcome Italy Echocardiography Relative risk Propensity score matching Cardiology Female Cardiology and Cardiovascular Medicine business Follow-Up Studies |
Zdroj: | The American journal of cardiology. 109(10) |
ISSN: | 1879-1913 |
Popis: | Comparisons of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis remain sparse or limited by a short follow-up. We sought to evaluate early and midterm outcomes of consecutive patients (n = 618) undergoing successful TAVI (n = 218) or isolated SAVR (n = 400) at 2 centers. The primary end point was incidence of Valvular Academic Research Consortium–defined major adverse cerebrovascular and cardiac events (MACCEs) up to 1 year. Control of potential confounders was attempted with extensive statistical adjustment by covariates and/or propensity score. In-hospital MACCEs occurred in 73 patients (11.8%) and was more frequent in patients treated with SAVR compared to those treated with TAVI (7.8% vs 14.0%, p = 0.022). After addressing potential confounders using 3 methods of statistical adjustment, SAVR was consistently associated with a higher risk of MACCEs than TAVI, with estimates of relative risk ranging from 2.2 to 2.6 at 30 days, 2.3 to 2.5 at 6 months, and 2.0 to 2.2 at 12 months. This difference was driven by an adjusted increased risk of life-threatening bleeding at 6 and 12 months and stroke at 12 months with SAVR. Conversely, no differences in adjusted risk of death, stroke and myocardial infarction were noted between TAVI and SAVR at each time point. In conclusion, in a large observational registry with admitted potential for selection bias and residual confounding, TAVI was not associated with a higher risk of 1-year MACCEs compared to SAVR. |
Databáze: | OpenAIRE |
Externí odkaz: |